

112年06月中部地區消化系同好會

- ★ 時間：112年06月01日（四） 17:30 – 21:00
- ★ 地點：台中金典酒店 13樓梅花廳（台中市西區健行路1049號）
- ★ 主持：陳家禹 主任
- ★ 學分：內科醫學會、消化系醫學會、台灣肝癌醫學會、消化系內視鏡醫學會

Time	Topic	Speaker	Moderator
17:30-17:50	Registration		
17:50-18:00	Opening		亞洲大學附屬醫院 肝膽腸胃科 陳家禹 主任
18:00-18:20	Case report: Rectal bleeding in a young man	亞洲大學附屬醫院 消化內科 許樹湖 醫師	
18:20-18:50	Efficacy and safety of lenvatinib monotherapy and lenvatinib-based combination therapy for patients with unresectable HCC: a real-world experience in CMUH	中國醫藥大學附設醫院 消化內科 王鴻偉 醫師	

18:50-19:20	Endoscopic treatments for esophageal disease	中國醫藥大學附設醫院 消化內科 丁俊夫 醫師
19:20-19:40	Update on the treatment of Helicobacter pylori infection: Where are we now?	台南市立安南醫院 許秉毅醫療副院長
19:40~21:00	Panel Discussion & Closing	

CURRICULUM VITAE

Name: Hung-Wei Wang (王鴻偉)

Institution/Organization:

1. Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
2. School of Medicine, China Medical University, Taichung, Taiwan

TEL : 04-22052121 ext. 12260

E-mail : D29280@mail.cmuh.org.tw; sdqw190@gmail.com

ORCID : <https://orcid.org/0000-0001-6574-1561>



Education:

M.D. (2001.9-2008.6), College of Medicine, Taipei Medical University, Taipei, Taiwan

Academic Appointment:

2020.8- Assistant Professor, Department of Internal Medicine, China Medical University

Professional Experience:

2009.8-2012.6 Resident, Department of Internal Medicine, Chang-Gung Memorial Hospital, Linkou branch, Taiwan

2012.7-2014.7 Fellowship, Division of Gastroenterology & Hepatology, Chang-Gung Memorial Hospital, Linkou branch, Taiwan

2014.8-2016.2 Attending Physician, Division of Gastroenterology & Hepatology, Department of Internal Medicine, Chang-Gung Memorial Hospital, Linkou branch, Taiwan

2016.4-present Attending Physician, Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan

Professional Affiliations and Memberships:

Member of the Taiwan Medical Association

Member and Specialist of the Society of Internal Medicine of Taiwan

Member of the Society of Ultrasound in Medicine of the Republic of China

Member and Specialist of the Gastroenterology Society of Taiwan

Member and Specialist of the Taiwan Liver Cancer Association

Member and Specialist of the Digestive Endoscopy Society of Taiwan

Member of the Taiwan Association for the Study of Small Intestinal Diseases


Member and Specialist of the Taiwan Academy of Tumor Ablation

Member of the Taiwan Association for the Study of the Liver

Publication (First author):

1. **Hung-Wei Wang**, Chia-Jung Kuo, Wey-Ran Lin, Chen-Ming Hsu, Yu-Pin Ho, Chun-Jung Lin,

- Kuang-Hua Chen, Ming-Yao Su, Cheng-Tang Chiu*. Barrett's esophagus and risk of esophageal adenocarcinoma: a retrospective analysis. *Advances in Digestive Medicine* (2015) 2, 135-140
2. **Wang HW**, Kuo CJ, Lin WR, Hsu CM, Ho YP, Lin CJ, Su MY, Chiu CT*, Wang CL, Chen KH: The clinical characteristics and manifestations of cytomegalovirus esophagitis. *Dis Esophagus*. 2016 May;29(4):392-399 (IF 2.822)
 3. **Hung-Wei Wang**, Chia-Jung Kuo, Wey-Ran Lin, Chen-Ming Hsu, Yu-Pin Ho, Chun-Jung Lin, Ming-Yao Su, Cheng-Tang Chiu*, Kuang-Hua Chen. Clinical characteristics and manifestation of herpes esophagitis: one single center experience in Taiwan. *Medicine (Baltimore)*. 2016 Apr;95(14):e3187 (IF 1.817)
 4. **Wang HW**, Peng CY*, Lai HC, Su WP, Lin CH, Chuang PH, Chen SH, Chen CH, Hsu WF, Huang GT. New noninvasive index for predicting liver fibrosis in Asian patients with chronic viral hepatitis. *Sci Rep*. 2017 Jun 12;7(1):3259 (IF 4.997)
 5. **Wang HW**, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Chuang PH, Wang JH, Lee MH, Chen CH*, Peng CY*. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy. *J Gastroenterol Hepatol*. 2019 Feb;34(2):442-449 (IF 4.369)
 6. **Hung-Wei Wang**, Hsueh-Chou Lai, Tsung-Hui Hu, Wen-Pang Su, Sheng-Nan Lu, Chia-Hsin Lin, Chao-Hung Hung, Po-Heng Chuang, Jing-Houng Wang, Mei-Hsuan Lee, Chien-Hung Chen*, Cheng-Yuan Peng*. On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma. *Cancers (Basel)*. 2020 May 7;12(5):1177. (IF 6.575)
 7. **Hung-Wei Wang**, Po-Heng Chuang, Wen-Pang Su, Jung-Ta Kao, Wei-Fan Hsu, Chun-Che Lin, Guan-Tarn Huang, Jaw-Town Lin, Hsueh-Chou Lai*, Cheng-Yuan Peng*. On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma. *Cancers (Basel)*. 2021 Jul 26;13(15):3758. (IF 6.575)
 8. **Hung-Wei Wang**, Pei-Chein Tsai, Chi-Yi Chen, Kuo-Chih Tseng, Hsueh-Chou Lai, Hsing-Tao Kuo, Chao-Hung Hung, Shui-Yi Tung, Jing-Houng Wang, Jyh-Jou Chen, Pei-Lun Lee, Ron-Nan Chien, Chun-Yen Lin, Chi-Chieh Yang, Gin-Ho Lo, Chi-Ming Tai, Chih-Wen Lin, Jia-Horng Kao, Chun-Jen Liu, Chen-Hua Liu, Sheng-Lei Yan, Ming-Jong Bair, Wei-Wen Su, Cheng-Hsin Chu, Chih-Jen Chen, Ching-Chu Lo, Pin-Nan Cheng, Yen-Cheng Chiu, Chia-Chi Wang, Jin-Shiung Cheng, Wei-Lun Tsai, Han-Chieh Lin, Yi-Hsiang Huang, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu*, Cheng-Yuan Peng*. Risk stratification of hepatocellular carcinoma incidence using a fibrosis-4-based prediction model in patients with chronic hepatitis C receiving antiviral therapy: a nationwide real-world Taiwanese cohort study. *Am J Cancer Res*. 2022 Jul 15;12(7):3164-3174. (IF 5.942)
 9. **Hung-Wei Wang**, Chi-Yi Chen, Hsueh-Chou Lai, Tsung-Hui Hu, Wen-Pang Su, Sheng-Nan Lu, Chao-Hung Hung, Po-Heng Chuang, Jing-Houng Wang, Chien-Hung Chen*, Cheng-Yuan Peng*. Prediction model of hepatocellular carcinoma in patients with hepatitis B virus-related compensated cirrhosis receiving antiviral therapy. *Am J Cancer Res*. 2023;13(2):526-537 (IF 5.942)



醫師介紹QR CODE

丁俊夫 Chun-Fu Ting 消化系內視鏡腫瘤手術科主任

消化系

丁俊夫醫師的專長為各種肝膽腸胃疾病診治，尤其擅長各種治療性內視鏡，例如以內視鏡黏膜下腫瘤切除術(ESD)治療各種消化道腫瘤(如：早期咽喉癌，早期食道癌，早期胃癌，腸胃道黏膜下腫瘤，及早期大腸癌等)；以經口內視鏡食道肌肉切開術(POEM)治療食道弛緩不能症；及以內視鏡賁門整形術(ARMS)治療嚴重胃食道逆流，於2015年以內視鏡黏膜下腫瘤剝離術榮獲國家生技醫療品質標章認證，目前已執行逾570例案例，於技術及數量均居國內領先地位。

» 相關連結

初診掛號

複診掛號

學術研討

→ 專長

丁俊夫醫師的專長為各種肝膽腸胃疾病診治，尤其擅長各種治療性內視鏡，例如以內視鏡黏膜下腫瘤切除術(ESD)治療各種消化道腫瘤(如：早期咽喉癌，早期食道癌，早期胃癌，腸胃道黏膜下腫瘤，及早期大腸癌等)；以經口內視鏡食道肌肉切開術(POEM)治療食道弛緩不能症；及以內視鏡賁門整形術(ARMS)治療嚴重胃食道逆流，於2015年以內視鏡黏膜下腫瘤剝離術榮獲國家生技醫療品質標章認證，目前已執行逾570例案例，於技術及數量均居國內領先地位。

→ 現職

- 中國醫藥大學附設醫院 內科部消化系內視鏡腫瘤手術科 主任

→ 學歷

- 中國醫藥大學 中醫學系 學士

→ 經歷

- 中國醫藥大學附設醫院 內科 住院醫師
- 中國醫藥大學附設醫院 內科部消化系 研究醫師
- 中國醫藥大學附設醫院 內科部消化系 主治醫師
- 日本東京國立癌症醫學中心 訓練員



許秉毅 醫療副院長、主治醫師

內科部

消化內科

專長：幽門螺旋桿菌、胃食道逆流疾病、大腸癌、消化性潰瘍、胃癌、肝炎、肝硬化、肝癌、腸道微菌叢。

初診掛號

複診掛號

→ 專長

幽門螺旋桿菌、胃食道逆流疾病、大腸癌、消化性潰瘍、胃癌、肝炎、肝硬化、肝癌、腸道微菌叢。

→ 學歷

- 台北醫學大學醫學系畢業
- 美國德州休士頓貝勒醫學院臨床研究員
- 醫務管理研究所碩士學分班結業
- 日本東京國立癌症研究中心參訪學者

→ 教職

- 教授